GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (NAS:ANGO) » Definitions » Additional Paid-In Capital

AngioDynamics (AngioDynamics) Additional Paid-In Capital

: $608.6 Mil(As of Feb. 2024)
View and export this data going back to 2004. Start your Free Trial

AngioDynamics's quarterly additional paid-in capital increased from Aug. 2023 ($603.8 Mil) to Nov. 2023 ($605.3 Mil) and increased from Nov. 2023 ($605.3 Mil) to Feb. 2024 ($608.6 Mil).

AngioDynamics's annual additional paid-in capital increased from May. 2021 ($573.5 Mil) to May. 2022 ($586.9 Mil) and increased from May. 2022 ($586.9 Mil) to May. 2023 ($599.2 Mil).


AngioDynamics Additional Paid-In Capital Historical Data

The historical data trend for AngioDynamics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Additional Paid-In Capital
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 555.04 561.87 573.51 586.88 599.21

AngioDynamics Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Additional Paid-In Capital Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 596.23 599.21 603.76 605.28 608.59

AngioDynamics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

AngioDynamics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of AngioDynamics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


AngioDynamics (AngioDynamics) Business Description

Traded in Other Exchanges
Address
14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.
Executives
Lorinda Burgess director 22 WEST FRONTAG ROAD, NORTHBROOK IL 60093
Karen A Licitra director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael E Tarnoff director C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Scott Centea officer: SVP/GM, VIT C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Dave Helsel officer: SVP Global Operations and R&D 400 WOOD ROAD, BRAINTREE MA 02184
Laura Piccinini officer: SVP International C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110
Stephen A Trowbridge officer: SVP and General Counsel 14 PLAZA DRIVE, LATHAM NY 120110
James C Clemmer director, officer: President and CEO COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Wesley Johnson director
Chad Thomas Campbell officer: SVP/GM, Vascular Access 140 POKANOKET PATH, WRENTHAM MA 02093
Warren Jr Nighan officer: SVP Quality and Regulatory ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Richard C Rosenzweig officer: SVP and General Counsel C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kevin J Gould director 247 WASHINGTON STREET, DUXBURY MA 02332
Brent J. Boucher officer: SVP and GM of Oncology 14 PLAZA DRIVE, LATHAM NY 12110
Michael Greiner officer: EVP and CFO C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421